Sanofi to Acquire Bioverativ to Treat Hemophilia
Shots:
- Sanofi acquires Bioverativ- in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value as $11.6B
- The focus of the agreement is to combine Bioverativ’s expertise with its platform for the advancement of fitusiran to treat Hemophilia A and B and further strengthening Sanofi’s footprints in rare diseases
- Fitusiran is a once-monthly RNA interference (RNAi) therapeutic- targeted for hemophilia A and B with and without inhibitors
Ref: Eli Lilly | Image: The Street
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com